Amanda K. Sykes

Statistics

Publications

Citations

190

H-Index

Active since

2011

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

Amanda K. Sykes is an author at Eli Lilly (United States) specializing in oncology pharmacology, pharmacology, and pharmacokinetics of anticancer drugs.

Publications per year

2011–2020

Publications

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty et al. · Molecular Cancer Therapeutics · 2019 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

Sonya C. Tate, Amanda K. Sykes, Palaniappan Kulanthaivel et al. · Clinical Pharmacokinetics · 2017 · 69 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

George R. Simon, Robert Ilaria, Mika A. Sovak et al. · Cancer Chemotherapy and Pharmacology · 2011 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

Emmanuel Chigutsa, Siva Rama Prasad Kambhampati, Amanda K. Sykes et al. · CPT Pharmacometrics & Systems Pharmacology · 2020 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–4 of 4